ALG 097111
Alternative Names: ALG-097111Latest Information Update: 30 May 2025
At a glance
- Originator Aligos Therapeutics; Centre for Drug Design and Discovery; Rega Institute for Medical Research
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 30 May 2025 Discontinued - Preclinical for COVID-2019 infections in Belgium (unspecified route) prior to May 2025 (Aligos Therapeutics pipeline, May 2025)
- 30 May 2025 Discontinued - Preclinical for COVID-2019 infections in USA (unspecified route) prior to May 2025 (Aligos Therapeutics pipeline, May 2025)
- 28 Jan 2025 No recent reports of development identified for preclinical development in COVID-2019-infections in Belgium